ChemRar Ltd
ChemRar Ltd is a privately held Russian pharmaceutical group that operates a vertically integrated drug-development and GMP manufacturing platform — from compound discovery through APIs and finished dosage forms — serving Russian state healthcare procurement, EAEU pharmaceutical developers via CRO/CDMO services, and researchers with a 1.6M-compound screening library.
- Company typePrivate
- Founded1990
- HeadquartersKhimki, Russia
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What ChemRar Ltd does
ChemRar Ltd (operating as Group of Companies KhimRar / ЦВТ ХимРар) is a privately held Russian pharmaceutical group founded in 1990 and headquartered in Khimki, Moscow Oblast, with 501–1,000 employees and a vertically integrated drug-development platform spanning compound discovery, GLP preclinical studies, ADME and toxicology, GMP API manufacturing, and finished dosage form production. Its operating subsidiaries include NII KhimRar (research), AFS-Technologies (API GMP), Research Institute of Chemical Diversity (finished products GMP), BioIntegrator (biotech/vaccines), Viriom (HIV/Hep/influenza), CardioSystemPharma (cardiac surgery), Elpida (Hepatitis C commercialization), and IFARMA (CRO), plus the Kromis joint venture with RDIF for Avifavir.
The group's marketed portfolio of approximately 20 innovative and generic products includes Avifavir (favipiravir-based COVID-19 treatment, world's first registered), Elpida / Elpid (elsulfavirine NNRTI for first-line HIV, co-developed with F. Hoffmann-La Roche), Konesko (ravidasvir, pan-genotypic NS5A inhibitor for Hepatitis C), Normacor (cardioplegia solution and delivery systems), AviNeuro (CNS pipeline), and NewVac (oncology). Underpinning the platform is a 1.6M+ compound / 75,000 building-block screening library and an API manufacturing complex opened in Khimki in May 2026 with up to 50 tonnes annual capacity and approximately 2 billion RUB of capital investment.
ChemRar earns revenue through four streams: (1) domestic pharmaceutical product sales — primarily to Russian state healthcare buyers via federal procurement and inclusion on the vital and essential drugs list (ZHNVP); (2) CRO services including chemical synthesis, ADME, OECD-aligned toxicology, and registration support for Russian and international pharma; (3) compound library supply and HTS services; and (4) contract GMP manufacturing of APIs and clinical batches for EAEU and international developers. Go-to-market is enterprise field sales to government institutions and industry partners, supplemented by direct CRO/CDMO engagement; pricing is not publicly disclosed and is largely quote-based for services and government-tender-driven for products. The company operates one of the few full-cycle domestic pharma platforms in Russia, with deep ties to MIPT, Skolkovo, Minpromtorg and Minzdrav.
ChemRar Ltd firmographics
Firmographics- Name
- ChemRar Ltd
- Legal name
- ООО «ХимРар»
- Website
- https://chemrar.ru
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- ChemRar Ltd is a privately held Russian pharmaceutical group that operates a vertically integrated drug-development and GMP manufacturing platform — from compound discovery through APIs and finished dosage forms — serving Russian state healthcare procurement, EAEU pharmaceutical developers via CRO/CDMO services, and researchers with a 1.6M-compound screening library.
- Ownership category
- akta.pro rank
ChemRar Ltd industry classification
Industry- Product category
- Pharmaceutical R&D and Manufacturing Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)
Keywords
Where ChemRar Ltd is headquartered
LocationHeadquarters
- HQ city
- Khimki
- HQ country
- Russia
- HQ region
- Europe
Offices2 records
Markets served
ChemRar Ltd business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical product sales: Sale of proprietary and import-substituting pharmaceutical products developed and manufactured in-house. Portfolio includes approximately 20 innovative and generic drug products including APIs. Major products include Avifavir (COVID-19), Elpid (HIV), Konesko (Hepatitis C), Normacor (cardioplegia solution), and products for oncology and CNS.
- Contract research and development services: CRO services including preclinical studies (in vitro/in vivo), chemical synthesis, ADME, pharmacokinetics, toxicology, pharmaceutical development, and manufacturing of clinical batches. Services are provided to international and Russian pharmaceutical companies on a contract basis.
- Compound library sales and supply: Supply of chemical compound libraries and building blocks for screening to pharmaceutical developers in Russia and internationally. Collection of 1.6M+ compounds available for in silico and in vitro screening.
- Contract manufacturing (GMP production): Contract manufacturing of pharmaceutical substances (APIs) and finished dosage forms for clinical trials and commercial batches under GMP for EAEU and international markets.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
ChemRar Ltd product offering
Product offeringCore offering
ChemRar Ltd is a vertically integrated pharmaceutical R&D and manufacturing group providing full-cycle drug development services from molecule discovery and preclinical research through API and finished dosage form manufacturing under GMP. The company develops and sells proprietary innovative drugs (Avifavir for COVID-19, Elpida for HIV, Konesko for Hepatitis C, Normacor for cardiac surgery, AviNeuro for CNS, NewVac for oncology) and offers CRO/CDMO services to other pharmaceutical companies.
Product overview
ChemRar Group is a Russian pharmaceutical company providing full-cycle drug development and manufacturing services from early molecule discovery through preclinical and clinical studies to market registration. The portfolio includes innovative drugs (Avifavir for COVID-19, Elpida for HIV, Konesko for Hepatitis C, Avineuro for CNS, NewVac for oncology, CardioSystemPharma for cardiology) and generic drugs. The company operates contract research services including chemical synthesis with 1.6M compound library, in vitro/in vivo preclinical studies, ADME/toxicology, pharmaceutical development, and GMP clinical batch manufacturing across multiple production facilities (NII KhimRar, AFS-Technologies, IIHR).
Differentiator
Problem solved
Functional benefit
Brands
- Avifavir: First in the world registered favipiravir-based drug for COVID-19 treatment
- ELPIDA
- Konesko
- Normacor
- NewVak
- AviNeuro
- BioIntegrator
- AFS-Technologies
- Research Institute of Chemical Diversity
Products and services
- Avifavir (Авифавир) First in the world registered favipiravir-based drug for treatment of COVID-19. Antiviral pharmaceutical composition with activity against SARS-CoV-2 and other RNA viruses including resistant forms of influenza, supplied to Russian healthcare providers and government procurement programs.
- Elpida (Элпида) Innovative Russian drug for first-line HIV treatment. Non-nucleoside reverse transcriptase inhibitor (NNRTI) new generation containing elsulfavirine as active substance, registered in Russia.
- Konesko (Конеско) Pan-genotypic direct-acting antiviral drug (ravidasvir), NS5A protein inhibitor, used in combination with sofosbuvir for treatment of chronic hepatitis C in various patient groups including those with cirrhosis and HIV co-infection.
- CardioSystemPharma (КардиоСистемФарма) Company developing and producing medical devices and drugs for cardiac surgery including Normacor cardioplegia solution and delivery systems, providing comprehensive domestic solutions for cardiosurgical clinics.
- NewVac (НьюВак) Personalized and combination approaches in cancer therapy. Part of the innovative drug development portfolio.
- AviNeuro (Авинейро) Innovations for people suffering from CNS diseases and their relatives. CNS-focused drug development projects.
- R&D Center contract services Full-cycle contract research services including preclinical studies (in vitro and in vivo), chemical synthesis, pharmaceutical development, GMP manufacturing of clinical batches, and registration support for innovative and generic drugs, provided to pharmaceutical and biotech companies.
- Chemical compound libraries Collection of over 1.6 million chemical compounds and 75,000 building blocks for biological screening and preclinical research, including focused libraries, annotated libraries, and diverse libraries for high-throughput screening (HTS).
- Pharmaceutical substance (API) development Contract development of active pharmaceutical ingredients (APIs) based on small molecules with technology transfer support to Russian production sites, including laboratory and pilot-scale synthesis methods and GMP manufacturing.
- Clinical batch manufacturing Contract manufacturing of drug product clinical batches for clinical trials and commercial batches for EAEU and international markets, provided from GMP certified production facilities.
- ADME studies In vitro ADME studies including liver microsome stability, S9 fraction stability, hepatocyte stability, plasma chemical stability, protein binding, membrane permeability (PAMPA, Caco-2), and cytochrome P450 inhibition studies.
- GLP toxicology services Preclinical toxicology studies including acute toxicity, subchronic and chronic toxicity, reproductive toxicity, and genotoxicity testing conducted per OECD guidelines at the GLP-compliant Testing Center.
- New API production complex (Khimki) New GMP-certified pharmaceutical substance production complex with capacity up to 50 tons of APIs per year, producing substances for HIV, hepatitis C, oncology, metabolic, and CNS drugs, employing over 100 qualified specialists.
Quantifiable outcome
- Avifavir demonstrated ability to block coronavirus replication, relieve symptoms, and reduce disease duration by half compared to standard therapy.
- +3 more outcomes
Companies that use ChemRar Ltd
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
ChemRar Ltd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ChemRar Ltd partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered major and core.
- Chinese research institutions (National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya, National AIDS Prevention and Control Center, First Affiliated Hospital of Zhejiang University)majorAt SPIEF 2026, KhimRar hosted a session on Russia-China cooperation in fighting HIV and oncology. Chinese partners shared achievements in HIV vaccine development (phase 3 clinical trials), CAR-NK cell therapy, and invited Russian scientists to participate in joint clinical research programs. Session moderated by KhimRar's IFARMA subsidiary.
- BioPharm Cluster Northern (Biofarmklaster Severny)majorKhimRar serves as an anchor partner of the Northern Biopharma Cluster established at MIPT (Physico-Technical Institute), alongside leading market players including Protek Group, Akrikhin, FNC Pharmzashchita, and Geropharm since 2011.
- Moscow Institute of Physics and Technology (MIPT)majorSince 2011, KhimRar has cooperated with MIPT for training researchers and engineers for the pharmaceutical industry and serves as the base organization for the Department of Innovative Pharmaceuticals, Medical Equipment and Biotechnologies at MIPT. KhimRar also co-initiated the creation of the FизTeкh XXI science-education cluster at MIPT.
- F. Hoffmann-La Roche LtdcoreRoche partnered with Viriom (KhimRar subsidiary) in the development of Elpid (elsulfavine), an innovative NNRTI for first-line HIV treatment. The partnership was supported by the Russian Ministry of Industry and Trade under the Pharma-2020 federal program and the Skolkovo Foundation.
- Skolkovo FoundationmajorKhimRar has been a key partner of the Skolkovo Foundation in the Life Sciences area since 2014. The foundation provides support for innovative pharmaceutical R&D projects including Elpid (elsulfavine) for HIV treatment.
- Ministry of Industry and Trade of Russia (Minpromtorg Rossii)majorThe Ministry of Industry and Trade provided co-financing and support for KhimRar's development of Elpid and other innovative drugs under the Pharma-2020 federal program.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
ChemRar Ltd competitors and assessment
Company assessmentBroad incumbents
- WuXi AppTec: Global CRO/CDMO offering preclinical research, API development and GMP manufacturing services. Compares to ChemRar's contract research and CDMO business lines at a vastly larger scale and global footprint.
- Lonza: Global CDMO with leading small-molecule API and finished dosage form GMP capabilities. Comparable to ChemRar's CDMO business (AFS-Technologies and IIHR) at a much larger scale across multiple geographies.
Direct peers
- R-Pharm: Russian pharma group with a diversified portfolio of innovative, generic and biosimilar products plus contract manufacturing. Competes with ChemRar in federal tenders and benefits from the same state import-substitution programs.
- Pharmasyntez: Major Russian vertically integrated pharmaceutical manufacturer with a comparable full-cycle model covering generics, APIs, and innovative drugs. Directly competes with ChemRar for state procurement and import-substitution mandates in Russia.
- NovaMedica: Russian pharmaceutical company focused on innovative and generic drug development with international technology-transfer partnerships. Comparable to ChemRar's hybrid model of in-house R&D plus partnership-led commercialization.
- Petrovax: Russian innovative pharma and vaccine manufacturer with strong state procurement and international partnership exposure. Comparable in its mix of proprietary innovative products, GMP manufacturing, and government-channel go-to-market.
- Valenta Pharm: Russian branded pharmaceutical company developing and marketing innovative and generic products across CNS, anti-infectives and other therapeutic areas. Comparable in domestic-market focus and product portfolio breadth.
- Geropharm: Russian pharmaceutical manufacturer with a strong portfolio in socially significant diseases (notably diabetes/insulin) and government procurement contracts. Direct comparator for ChemRar's innovative-drug-plus-state-channel strategy.
- Akrikhin: Russian generic pharmaceutical manufacturer with GMP production facilities and a substantial presence in federal and regional procurement. Overlaps with ChemRar's generics portfolio and finished dosage form manufacturing capabilities.
- BIOCAD: Russian biotech company combining innovative biologics development with in-house GMP manufacturing and state procurement contracts. Closely comparable in business model and end-customers (Russian government healthcare programs).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ChemRar Ltd social profiles
Digital presenceChemRar Ltd compliance and trust
Trust signalCompliance4 records
ChemRar Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
ChemRar Ltd leadership team
Management profileNumber of profiles
Profiles4 records
ChemRar Ltd subsidiaries and ownership
Company hierarchySubsidiaries9 records
ChemRar Ltd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ChemRar Ltd M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ChemRar Ltd
What does ChemRar Ltd do?
ChemRar Ltd is a vertically integrated pharmaceutical R&D and manufacturing group providing full-cycle drug development services from molecule discovery and preclinical research through API and finished dosage form manufacturing under GMP. The company develops and sells proprietary innovative drugs (Avifavir for COVID-19, Elpida for HIV, Konesko for Hepatitis C, Normacor for cardiac surgery, AviNeuro for CNS, NewVac for oncology) and offers CRO/CDMO services to other pharmaceutical companies.
Is ChemRar Ltd a public or private company?
ChemRar Ltd is a private company. It is classified as unknown and is currently operating.
When was ChemRar Ltd founded?
ChemRar Ltd was founded in 1990. It employs 501 to 1,000 people.
Where is ChemRar Ltd based?
ChemRar Ltd is headquartered in Khimki, Russia, in the Europe region.
How does ChemRar Ltd make money?
Four revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are contract research and development services, compound library sales and supply and contract manufacturing (GMP production).
Who are ChemRar Ltd's main competitors?
Broad incumbents on record are WuXi AppTec and Lonza. Direct peers are R-Pharm, Pharmasyntez, NovaMedica, Petrovax, Valenta Pharm, Geropharm, Akrikhin and BIOCAD.
Does ChemRar Ltd have an API?
No public API is recorded for ChemRar Ltd.
What industry is ChemRar Ltd in?
ChemRar Ltd's product category is Pharmaceutical R&D and Manufacturing Services. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 325412 and its SIC code is 2834.